You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

NASACORT ALLERGY 24 HOUR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nasacort Allergy 24 Hour patents expire, and when can generic versions of Nasacort Allergy 24 Hour launch?

Nasacort Allergy 24 Hour is a drug marketed by Chattem Sanofi and is included in one NDA.

The generic ingredient in NASACORT ALLERGY 24 HOUR is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nasacort Allergy 24 Hour

A generic version of NASACORT ALLERGY 24 HOUR was approved as triamcinolone acetonide by TARO on October 1st, 1986.

  Try a Trial

Drug patent expirations by year for NASACORT ALLERGY 24 HOUR
Recent Clinical Trials for NASACORT ALLERGY 24 HOUR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Gail GauvreauN/A
Stanford UniversityPhase 4
SanofiPhase 4

See all NASACORT ALLERGY 24 HOUR clinical trials

Pharmacology for NASACORT ALLERGY 24 HOUR

US Patents and Regulatory Information for NASACORT ALLERGY 24 HOUR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chattem Sanofi NASACORT ALLERGY 24 HOUR triamcinolone acetonide SPRAY, METERED;NASAL 020468-002 Oct 11, 2013 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NASACORT ALLERGY 24 HOUR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chattem Sanofi NASACORT ALLERGY 24 HOUR triamcinolone acetonide SPRAY, METERED;NASAL 020468-002 Oct 11, 2013 ⤷  Try a Trial ⤷  Try a Trial
Chattem Sanofi NASACORT ALLERGY 24 HOUR triamcinolone acetonide SPRAY, METERED;NASAL 020468-002 Oct 11, 2013 ⤷  Try a Trial ⤷  Try a Trial
Chattem Sanofi NASACORT ALLERGY 24 HOUR triamcinolone acetonide SPRAY, METERED;NASAL 020468-002 Oct 11, 2013 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NASACORT ALLERGY 24 HOUR

See the table below for patents covering NASACORT ALLERGY 24 HOUR around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 9800178 ⤷  Try a Trial
China 1228712 ⤷  Try a Trial
Poland 194269 ⤷  Try a Trial
Australia 737506 ⤷  Try a Trial
South Korea 100383601 ⤷  Try a Trial
Australia 3647197 ⤷  Try a Trial
Hungary 9903503 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.